Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance - PubMed
4 hours ago
- #Paclitaxel resistance
- #Triple-negative breast cancer
- #γ-secretase inhibitor
- Erythrinin C (EC) targets γ-secretase signaling to suppress triple-negative breast cancer (TNBC) progression.
- EC reverses paclitaxel (Taxol) resistance in TNBC/Taxol cells, enhancing chemotherapy efficacy.
- The study identifies EC as a γ-secretase inhibitor, showing anti-TNBC activity in vitro and in vivo.
- Low expression of PSEN-1, a γ-secretase subunit, inhibits TNBC cell malignancy.
- Combination therapy of EC and Taxol significantly reduces tumor growth in xenograft models.
- EC is highlighted as a promising natural therapeutic candidate for TNBC treatment.